Short Course Regimens for Treatment of PKDL (Sudan)
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This is an open label, randomized non comparative phase II clinical trial conducted on
parallel groups, to assess the safety and efficacy of the combination of Paromomycin (20
mg/kg/d) IM for 14 days and Miltefosine (allometric dosing) oral for 42 days, and a
combination of AmBisome® (20 mg/kg total dose) IV over 7 days and Miltefosine oral for 28
days (allometric dosing) for the treatment of PKDL patients in Sudan.
Phase:
Phase 2
Details
Lead Sponsor:
Drugs for Neglected Diseases
Treatments:
Amphotericin B Liposomal amphotericin B Miltefosine Paromomycin